The Quantellect read.As of Nov 19, 2026, 8 active firms cover Alignment Healthcare LLC: 5 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $9.00 to $30.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $14.57 sits 116% above the current $6.74. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 31% this year and 25% next, consensus EPS building from about $0.15 next quarter toward $0.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy563%
Neutral338%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.57
+116.2% upside
Average target across 7 active firms as of Nov 19, 2026 vs $6.74 current
Highest Target$30.00
Average Target$14.57
Lowest Target$9.00
Detailed analyst forecasts for ALHC
Showing 1–10 of 10 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 5 of 8 active firms rate ALHC a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ALHC EPS & revenue forecast
EPS · NEXT QUARTER
$0.15
Range $0.13 – $0.16 · 3 analysts · +21% YoY
Next period, 3 analysts expect Alignment Healthcare LLC to earn $0.15 a share (range $0.13 – $0.16), versus $0.12 a year earlier. Full-year consensus is $0.27, growing to $0.56 the year after.
REVENUE · NEXT QUARTER
$1.6B
Range $1.5B – $1.6B · 3 analysts · +32% YoY
Revenue is expected to reach $1.6B (range $1.5B – $1.6B), +32.0% year-over-year. Full-year consensus is $5.3B, rising to $6.6B next year.
Top analysts covering Alignment Healthcare LLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ALHC.
#1
Kevin Caliendo
UBS · Rank #165
Neutral
$21.00+211.6% to target
Overall win rate
42%
+ Follow
#2
Andrew Mok
Barclays · Rank #385
Neutral
$10.00+48.4% to target
Overall win rate
39%
+ Follow
#3
JS
John Stansel
JP Morgan
Buy
$8.00+18.7% to target
Coverage
—
+ Follow
#4
AM
Andrew Mok CFA
Barclays
Neutral
$9.00+33.5% to target
Coverage
—
+ Follow
#5
MG
Matthew Gillmor CFA
KeyBanc
Neutral
No targeton ALHC
Coverage
—
+ Follow
ALHC stock forecast FAQ
What is ALHC's average 12-month price target?+
The 7 active firms with a live target average $14.57 for Alignment Healthcare LLC over the next 12 months, ranging from a $30.00 high to a $9.00 low, as of Nov 19, 2026.
Is ALHC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ALHC?+
The Street-high target is $30.00 (Piper Sandler), and the Street-low is $9.00 (UBS). The average of all 7 active-firm targets is $14.57.
How many active Wall Street firms cover ALHC?+
8 active firms have a recognized rating on Alignment Healthcare LLC as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ALHC?+
Among analysts who currently cover ALHC, Kevin Caliendo of UBS has the strongest overall Quantellect track record (Rank #165). Their current call is Neutral with a $21.00 target.
What is Alignment Healthcare LLC's projected EPS for next quarter?+
The consensus estimate is $0.15 per share (range $0.13 – $0.16) across 3 analysts. Full-year EPS is projected at $0.27, rising to $0.56 the following year.
How much revenue is Alignment Healthcare LLC expected to report next quarter?+
Consensus revenue is $1.6B (range $1.5B – $1.6B). Full-year revenue is projected at $5.3B, growing to $6.6B next year.
Have analysts been upgrading or downgrading ALHC lately?+
As of Nov 19, 2026, 5 of 8 active firms rate ALHC a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ALHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.